The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo’s DS-8201 Gets Breakthrough Therapy Designation
August 31, 2017
- Fujifilm Holdings Aims to Achieve 500 Billion Yen in Healthcare Sales in FY2019
August 31, 2017
- Mitsubishi Tanabe Chief Looks to Tap Canaglu’s CV Outcome Data to Boost Sales
August 30, 2017
- Boston Pharma Gets Rights to Daiichi Sankyo’s Preclinical RET Inhibitor
August 30, 2017
- BMS, Daiichi Sankyo to Collaborate on Opdivo-DS-8201 Combo
August 30, 2017
- Mitsubishi Tanabe to Create New Business by Fusing LLPs with Digital Technologies
August 30, 2017
- Takeda Divesting Laboratory Animal Unit amid R&D Realignment Drive
August 29, 2017
- Suzuken Group to Shed 350 Jobs as It Seeks SGA Efficiency
August 29, 2017
- FGF23 Antibody Burosumab Filed in US: Kyowa Kirin, Ultragenyx
August 28, 2017
- Poteligeo Earns FDA’s BT Designation for CTCL: Kyowa Kirin
August 28, 2017
- Spinraza to Hit Japan Market on August 30
August 28, 2017
- Astellas to Integrate Regenerative Medicine Research into US Unit
August 25, 2017
- Otsuka, Mylan Ink TB Deal for 29 Developing Countries
August 25, 2017
- Bayer Instruction Existed in Patient Info Acquisition, Sales Rep Tells Govt Panel
August 25, 2017
- Japan NDA Filed for Lymphoma Med Obinutuzumab: Chugai/Nippon Shinyaku
August 24, 2017
- CureApp to Begin Clinical Trial of Japan’s First “Treatment App” in October
August 24, 2017
- 1st Patient Dosed in PIII for Gilteritinib as Post-HCT AML Maintenance Therapy: Astellas
August 23, 2017
- Takeda Files Japan NDA for Entyvio
August 23, 2017
- External Activities of Takeda Unit Axcelead to Go Full Throttle This Autumn: President
August 23, 2017
- Japan’s “Advanced Drug” Market Put at 1.4 Trillion Yen in 2016: Fuji Keizai
August 22, 2017
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…